8-K: Palisade Bio Advances PALI-2108 Trials, Reports Q3 2026 Results

Palisade Bio announced third quarter 2026 financial results, highlighting progress in its PALI-2108 clinical development for inflammatory bowel disease, including patient dosing in the ASCENTRA-UC trial and FDA clearance for ASCENTRA-CD.

Summary

• Palisade Bio reported financial results for the third quarter ended September 30, 2026.
• The company dosed the first patient in its global Phase 2b ASCENTRA-UC trial for ulcerative colitis on October 27, 2026.
• Enrollment for the ASCENTRA-UC trial is targeted to complete with topline results expected in Q4 2027.
• The FDA cleared the IND application for the Phase 2a ASCENTRA-CD trial in Crohn's disease on September 22, 2026, with enrollment targeted for Q1 2027.
• Research and development expenses increased to $10.6 million for Q3 2026 from $1.4 million in Q3 2025.
• General and administrative expenses rose to $5.1 million for Q3 2026 from $1.5 million in Q3 2025.
• The net loss for Q3 2026 was $14.6 million ($0.07 per share), compared to a net loss of $2.9 million ($0.38 per share) in Q3 2025.
• As of September 30, 2026, the company had $113.6 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with significant clinical trial progress and a strong cash position, though increased operating expenses and net loss are noted.

Positives

• First patient dosed in the global Phase 2b ASCENTRA-UC trial for ulcerative colitis on October 27, 2026.
• 29 of 30 planned U.S. clinical sites activated for ASCENTRA-UC.
• Health Canada CTA clearance received in September 2026, and regulatory clearance in the Republic of Georgia in October 2026 for ASCENTRA-UC global expansion.
• FDA cleared the IND application for the Phase 2a ASCENTRA-CD trial in Crohn's disease on September 22, 2026.
• New clinical and translational data for PALI-2108 presented at ACG and UEG Week 2026, including two Presidential Poster Awards.
• Strong cash position of $113.6 million as of September 30, 2026, expected to fund operations through key Phase 2 clinical milestones.
• PALI-2108 demonstrated potential for targeted intestinal drug exposure and early clinical activity in presentations.

Negatives

• Research and development expenses increased significantly to $10.6 million in Q3 2026 from $1.4 million in Q3 2025.
• General and administrative expenses also increased significantly to $5.1 million in Q3 2026 from $1.5 million in Q3 2025.
• Net loss widened to $14.6 million in Q3 2026 from $2.9 million in Q3 2025.
• Basic and diluted net loss per common share increased to $0.07 in Q3 2026 from $0.38 in Q3 2025 (note: this appears to be a typo in the original filing, as $0.07 is better than $0.38; assuming the filing meant to report a loss per share of $0.07 for Q3 2026 and $0.38 for Q3 2025, indicating a worse loss per share in 2025).
• Cash and cash equivalents decreased from $133.6 million at December 31, 2025, to $113.6 million at September 30, 2026.

Risks

• The timing of enrollment, commencement, and completion of clinical trials.
• Reliance on PALI-2108 and its early stage of clinical development.
• Ability to activate clinical sites on the anticipated timeline.
• Timing and outcome of regulatory reviews of clinical trial applications outside the United States.
• Reliance on third parties, including contract research organizations, clinical sites, and contract manufacturers.
• Risk that prior results from limited patient studies will not be replicated in ongoing or future studies.
• Risk that safety or tolerability findings emerge in larger, controlled studies.
• Need for additional capital to complete clinical development programs.

Future Outlook

The company expects to fund operations through key Phase 2 clinical milestones with its current cash position. Topline results from the ASCENTRA-UC trial are anticipated in Q4 2027, and the primary efficacy readout for ASCENTRA-CD is expected in Q1 2028. The company's forward-looking statements indicate potential for PALI-2108 as a differentiated, once-daily oral treatment for IBD.

Management Comments

• "ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress."
• "In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108s potential as a differentiated, once-daily oral treatment for patients living with IBD."
• "Now that ASCENTRA-UC is underway, our priority is to maintain enrollment momentum and deliver the clinical data needed to establish PALI-2108s potential in ulcerative colitis. We expect the results to provide a clearer understanding of its ability to induce remission, reduce intestinal inflammation and support sustained disease control."
• "In Crohns disease, we are focused on preparing ASCENTRA-CD for initiation of enrollment in the first quarter of 2027. We are pursuing these programs with the goal of developing a treatment that, if approved, could offer patients an effective, well-tolerated treatment that fits into daily life through once-daily oral dosing."

Industry Context

StockSavvy.ai notes that Palisade Bio is operating in the competitive biopharmaceutical sector focused on immune-mediated and fibrotic diseases, specifically inflammatory bowel disease. The company's strategy centers on advancing PALI-2108, a novel oral therapy, through Phase 2 trials. This approach aligns with industry trends towards developing more targeted and convenient oral treatments for chronic conditions, aiming to differentiate from existing injectable or less targeted therapies.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and its cash runway are key factors influencing shareholder value. Increased expenses and net loss may be a concern, but clinical advancement is a positive driver.
• Patients: Potential for a new, differentiated, once-daily oral treatment for ulcerative colitis and Crohn's disease.
• Employees: Increased operating activities and employee-related expenses suggest potential for team growth and investment in personnel.
• Creditors: The company's substantial cash reserves provide a buffer for operational stability.

Next Steps

• Continue enrollment in the global Phase 2b ASCENTRA-UC trial.
• Expand global clinical footprint for ASCENTRA-UC.
• Initiate enrollment for the Phase 2a ASCENTRA-CD trial in Q1 2027.
• Continue manufacturing and clinical supply activities for PALI-2108.
• Support ongoing preclinical and translational research.
• Prepare for topline results from ASCENTRA-UC in Q4 2027.
• Prepare for primary efficacy readout from ASCENTRA-CD in Q1 2028.

Key Dates

Recommendation

Palisade Bio is making significant progress in its clinical development pipeline with PALI-2108, evidenced by patient dosing in ASCENTRA-UC and FDA clearance for ASCENTRA-CD. The company maintains a strong cash position sufficient for upcoming milestones. However, the increased operating expenses and widening net loss, coupled with the inherent risks of clinical-stage biopharmaceutical development, warrant a cautious 'hold' rating. Investors should monitor trial enrollment, data readouts, and future financing needs.

Keywords

PALI-2108, Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, Phase 2b Trial, Phase 2a Trial, Biopharmaceutical, Clinical Development